1
|
Ma Y, Yu M, Wang H. Development, validation and application of a UPLC-MS/MS method for simultaneous quantification of OPC-61815 and its metabolites tolvaptan, DM-4103 and DM-4107 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2024; 1242:124213. [PMID: 38909567 DOI: 10.1016/j.jchromb.2024.124213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2024] [Revised: 06/12/2024] [Accepted: 06/18/2024] [Indexed: 06/25/2024]
Abstract
OPC-61815 is an intravenous formulation vasopressin antagonist designed to treat heart failure patients, especially who have difficulty in oral intake. Tolvaptan together with DM-4103 and DM-4107 are considered as the major metabolites of OPC-61815 biotransformed in the liver via cytochrome P450 (CYP) 3A. An efficient and robust ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for quantification of OPC-61815 and its three metabolites in human plasma was developed and fully validated. To our best knowledge, it was the first published method that simultaneously quantified all of these four analytes in only one run. Simple and rapid sample preparation procedure and very short UPLC-MS/MS run time (3.5 min) offered OPC-61815 and its metabolites relatively high throughput detection, which was greatly beneficial to further clinical bio-sample analysis. The method showed good linearity and sufficient sensitivity in the range of 2.00-1000 ng/mL with a low limit of quantitation (2.00 ng/mL) for each analyte. For samples with concentrations above 1000 ng/mL, 100-fold dilution with blank plasma before sample preparation was accepted. High precision and accuracy, high selectivity and satisfactory recovery of this method were demonstrated. For all of the four analytes, no significant matrix effect or carry-over was observed. The stability of analytes and internal standards under different conditions were evaluated to ensure they were stable during the whole period of storage, preparation and detection. Also, re-injection reproducibility was investigated. In addition, the conversion test showed that almost no OPC-61815 converted into DM-4103 and DM-4107 during sample processing, while attention should be paid to the concentration difference between OPC-61815 and tolvaptan in bioanalysis. The developed UPLC-MS/MS method was successfully applied to an open, single and multiple dose administration phase I trial for monitoring the pharmacokinetics of OPC-61815. This work provided a promising way for further pharmacokinetic study of OPC-61815.
Collapse
Affiliation(s)
- Yufang Ma
- Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Mengyang Yu
- Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Hongyun Wang
- Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
| |
Collapse
|
2
|
Karadurmus L, Budak F, Cetinkaya A, Atici EB, Ozkan SA. Development of highly selective and sensitive molecularly imprinted polymer-based electrochemical sensors for tolvaptan assay in tablets and serum. ANALYTICAL METHODS : ADVANCING METHODS AND APPLICATIONS 2023; 15:5316-5322. [PMID: 37807938 DOI: 10.1039/d3ay01454a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/10/2023]
Abstract
In this research, two different molecularly imprinted polymer (MIP)-based electrochemical sensors were proposed for the determination of tolvaptan (TOL). Photopolymerization (PP) and thermal polymerization (TP) techniques were developed for the determination of TOL. The advantages of MIP were used to design an electrochemical sensor for selective and sensitive determination of TOL. TOL was determined on a glassy carbon electrode (GCE) using differential pulse voltammetry (DPV) for both techniques. Some important parameters affecting the sensor efficiency, such as template/monomer ratio, PP and TP time, drop volume, removal solutions, removal and rebinding time, etc., were optimized. The surface characterization of the proposed MIP-based electrochemical sensors was carried out with electrochemical characterization by electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV) methods. It was extended with the scanning electron microscopy (SEM) technique. Under optimal conditions, the developed sensors showed good linearity between 1.0 × 10-11 M and 1.0 × 10-10 M, and 2.5 × 10-11 M and 2.5 × 10-10 M for PP and TP, respectively. Low detection limits (2.89 × 10-12 M (PP) and 1.88 × 10-13 M (TP)) were also obtained for TOL determination. The applicability of the proposed sensor was evaluated using tablet and commercial human serum samples. Interference and imprinting factor studies verified the selectivity and specificity of the proposed sensors, and the efficiency of the sensors was verified using an unprinted polymer for comparison at each step.
Collapse
Affiliation(s)
- Leyla Karadurmus
- Department of Analytical Chemistry, Faculty of Pharmacy, Adıyaman University, Adıyaman, Turkey.
| | - Fatma Budak
- Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, 06560, Ankara, Turkey.
- Graduate School of Health Sciences, Ankara University, Ankara, Turkey
| | - Ahmet Cetinkaya
- Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, 06560, Ankara, Turkey.
- Graduate School of Health Sciences, Ankara University, Ankara, Turkey
| | | | - Sibel A Ozkan
- Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, 06560, Ankara, Turkey.
| |
Collapse
|
3
|
Liu YJ, Bian Y, Zhang Y, Zhang YX, Ren A, Lin SH, Feng XS, Zhang XY. Diuretics in Different Samples: Update on the Pretreatment and Analysis Techniques. Crit Rev Anal Chem 2023:1-33. [PMID: 37130012 DOI: 10.1080/10408347.2023.2202260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Diuretics are drugs that promote the excretion of water and electrolytes in the body and produce diuretic effects. Clinically, they are often used in the treatment of edema caused by various reasons and hypertension. In sports, diuretics are banned by the World Anti-Doping Agency (WADA). Therefore, in order to monitor blood drug concentration, identify drug quality and maintain the fairness of sports competition, accurate, rapid, highly selective and sensitive detection methods are essential. This review provides a comprehensive summary of the pretreatment and detection of diuretics in various samples since 2015. Commonly used techniques to extract diuretics include liquid-liquid extraction, liquid-phase microextraction, solid-phase extraction, solid-phase microextraction, among others. Determination methods include methods based on liquid chromatography, fluorescent spectroscopy, electrochemical sensor method, capillary electrophoresis and so on. The advantages and disadvantages of various pretreatment and analytical techniques are elaborated. In addition, future development prospects of these techniques are discussed.
Collapse
Affiliation(s)
- Ya-Jie Liu
- School of Pharmacy, China Medical University, Shenyang, China
| | - Yu Bian
- School of Pharmacy, China Medical University, Shenyang, China
| | - Yuan Zhang
- School of Pharmacy, China Medical University, Shenyang, China
| | - Yi-Xin Zhang
- School of Pharmacy, China Medical University, Shenyang, China
| | - Ai Ren
- School of Pharmacy, China Medical University, Shenyang, China
| | - Shu-Han Lin
- School of Food Science and Engineering, Dalian Ocean University, Dalian, China
| | - Xue-Song Feng
- School of Pharmacy, China Medical University, Shenyang, China
| | - Xin-Yuan Zhang
- School of Forensic Medicine, China Medical University, Shenyang, China
| |
Collapse
|
4
|
Khadernaick AB, Kumar GS, Sandhya P, Bhikshapathi D. A Highly Sensitive LC–MS/MS Method Development and Validation of Fedratinib in Human Plasma and Pharmacokinetic Evaluation in Healthy Rabbits. CURR PHARM ANAL 2021. [DOI: 10.2174/1573412916999200512121023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
A simple and sensitive quantitation analytical technique by liquid chromatography–tandem mass
spectrometry (LC-MS/MS) is essential for fedratinib in biological media with kinetic study in healthy rabbits.
Objective:
The main objectives of the present research work are to LC-MS/MS method development and validate procedure
for the quantitation of fedratinib and its application to kinetic study in rabbits.
Methods:
Separation of processed samples were employed on zorbax SB C18 column (50mm×4.6 mm) 3.5µm with a movable
phase of methanol, acetonitrile and 0.1% formic acid in the ratio of 30:60:10. The movable phase was monitored through
column at 0.8 ml/min flow rate. The drug and ibrutinib internal standard (IS) were evaluated by monitoring the transitions of
m/z -525.260/57.07 and 441.2/55.01 for fedratinib and IS respectively in multiple reaction monitoring mode.
Results:
The linear equation and coefficient of correlation (R2) results were y =0.00348x+0.00245 and
0.9984, respectively. Intra and inter-day precision RSD findings of the developed technique were
found in the range of 2.4 - 5.3% for the quality control (QC)-samples (252.56, 1804.0 and 2706 ng/ml).
The proposed method was subjected to pharmacokinetic study in healthy rabbits and the kinetic study,
fedratinib showed mean AUClast 13190±18.1 hr*ng/ml and Cmax was found to be 3550±4.31 ng/ml in
healthy rabbits.
Conclusion:
The validated method can be applicable for the pharmacokinetic and toxicokinetic studies in the clinical and
forensic analysis of fedratinib in different kinds of biological matrices successfully.
Collapse
Affiliation(s)
| | | | - Pamu Sandhya
- Department of Pharmaceutics, Shadan Women’s college of Pharmacy, Hyderabad, India
| | | |
Collapse
|
5
|
Ravi Y, Bhikshapathi D, Cheruku S, Rajkamal B. Development of Fast and Simple LC-ESI-MS/MS Technique for the Quantification of Regorafenib; Application to Pharmacokinetics in Healthy Rabbits. CURR PHARM ANAL 2021. [DOI: 10.2174/1573412916666191111144707] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
A simple quantification technique by liquid chromatography electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS) is required for regorafenib in biological matrices
with bioavailability studies in healthy rabbits, when compared with reported techniques.
Objective:
The main aim of the research work was to develop a validated LC-ESI-MS/MS technique
for the quantification of regorafenib and application to bioavailability studies in healthy rabbits.
Methods:
Chromatographic separation was achieved with hypersil-C18 analytical column (50mm×4.6 mm,
4μm) and mobile phase composition of acetonitrile and 5mM ammonium acetate in the proportion of
70:30. The mobile phase was infused into the column with high pressure to get a 0.7 ml/min flow rate.
The total retention time of the analyte is promising when compared with the existed methods for
regorafenib. Quantitation was processed by monitoring transitions of m/z -483.0/262.0 and 450.0/260.0
for regorafenib and internal standard respectively in multiple reaction monitoring.
Results:
The linearity equation and correlation coefficient (R2) findings were y =0.9948x+2.6624 and
0.998 respectively. The intra and inter-day precision of the developed technique was found between
1.00 – 8.50% for the QC-samples (2, 4, 240 and 480ng/ml). From bioavailability study, the drug was
shown Tmax of 3.688 ± 0.754; average AUC0→α and AUC0→t were 6476.81 ± 259.59 and 6213.845 ±
257.892 respectively and Cmax was found to be 676.91 ± 22.045 in healthy rabbits.
Conclusion:
The developed technique was validated and successfully applied in the pharmacokinetic
study of the drug (40 mg tablet) administered through the oral route in healthy rabbits.
Collapse
Affiliation(s)
- Yatha Ravi
- Department of Pharmacy, Mewar University, Chittorgarh, Rajasthan,India
| | | | - Shankar Cheruku
- Department of Pharmaceutical Analysis, Vijaya College of Pharmacy, Hyderabad,India
| | - Bigala Rajkamal
- Department of Pharmacy, Mewar University, Chittorgarh, Rajasthan,India
| |
Collapse
|
6
|
Pal S, Porwal K, Khanna K, Gautam MK, Malik MY, Rashid M, Macleod RJ, Wahajuddin M, Parameswaran V, Bellare JR, Chattopadhyay N. Oral dosing of pentoxifylline, a pan-phosphodiesterase inhibitor restores bone mass and quality in osteopenic rabbits by an osteogenic mechanism: A comparative study with human parathyroid hormone. Bone 2019; 123:28-38. [PMID: 30858147 DOI: 10.1016/j.bone.2019.03.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 03/06/2019] [Accepted: 03/08/2019] [Indexed: 10/27/2022]
Abstract
The non-selective phosphodiesterase inhibitor pentoxifylline (PTX) is used for the treatment of intermittent claudication due to artery occlusion. Previous studies in rodents have reported salutary effects of the intraperitoneal administration of PTX in segmental bone defect and fracture healing, as well as stimulation of bone formation. We determined the effect of orally dosed PTX in skeletally mature ovariectomized (OVX) rabbits with osteopenia. The half-maximal effective concentration (EC50) of PTX in rabbit bone marrow stromal cells was 3.07 ± 1.37 nM. The plasma PTX level was 2.05 ± 0.522 nM after a single oral dose of 12.5mg/kg, which was one-sixth of the adult human dose of PTX. Four months of daily oral dosing of PTX at 12.5 mg/kg to osteopenic rabbits completely restored bone mineral density, bone mineral content (BMC), microarchitecture and bone strength to the level of the sham-operated (ovary intact) group. The bone strength to BMC relationship between PTX and sham was similar. The bone restorative effect of PTX was observed in both axial and appendicular bones. In osteopenic rabbits, PTX increased serum amino-terminal propeptide, mineralized nodule formation by stromal cells and osteogenic gene expression in bone. PTX reversed decreased calcium weight percentage and poor crystal packing found in osteopenic rabbits. Furthermore, similar to parathyroid hormone (PTH), PTX had no effect on bone resorption. Taken together, our data show that PTX completely restored bone mass, bone strength and bone mineral properties by an anabolic mechanism. PTX has the potential to become an oral osteogenic drug for the treatment of post-menopausal osteoporosis.
Collapse
Affiliation(s)
- Subhashis Pal
- Division of Endocrinology, CSIR-Central Drug Research Institute, Council of Scientific and Industrial Research, Lucknow 226031, India
| | - Konica Porwal
- Division of Endocrinology, CSIR-Central Drug Research Institute, Council of Scientific and Industrial Research, Lucknow 226031, India
| | - Kunal Khanna
- Department of Chemical Engineering, Indian Institute of Technology-Bombay, Mumbai 400076, India
| | - Manoj Kumar Gautam
- Department of Mechanical Engineering, Indian Institute of Technology-Kanpur, Kanpur 208016, India
| | | | - Mamunur Rashid
- Division of Pharmaceutics, CDRI-CSIR, Lucknow 226031, India
| | - R John Macleod
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada
| | | | | | - Jayesh R Bellare
- Department of Chemical Engineering, Indian Institute of Technology-Bombay, Mumbai 400076, India
| | - Naibedya Chattopadhyay
- Division of Endocrinology, CSIR-Central Drug Research Institute, Council of Scientific and Industrial Research, Lucknow 226031, India.
| |
Collapse
|
7
|
A rapid and sensitive LC-MS/MS-ESI method for the determination of tolvaptan and its two main metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1027:158-64. [PMID: 27288933 DOI: 10.1016/j.jchromb.2016.03.032] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Revised: 03/17/2016] [Accepted: 03/19/2016] [Indexed: 11/21/2022]
Abstract
A liquid chromatography-tandem mass spectrometry (LC-MS) method to quantify tolvaptan and its two main metabolites and applied to human study was first developed and validated as a measure of compliance in clinical research. Because of the structure similarity of tolvaptan and its multiple metabolites, the method was optimized to obtain a chromatographic and MS separation of the endogenous interference and isotope ions as well as high analysis throughput. Tolvaptan, its two main metabolites and the internal standard were extracted from human serum (0.1mL) using solid-phase extraction, separated on a Waters nova-pak C18 column (150×3.9mm, 5μm) using isocratic elution with a mobile phase composed of acetonitrile, water and formic acid (65:35:0.25, v/v/v). The total run-time was shortened to 3.5min. The mass transition ranges under positive electrospray ionisation that were monitored for quantitation included m/z 449-252 for tolvaptan, m/z 479-252 for metabolite DM-4103, m/z 481-252 for metabolite DM-4107 and m/z 463-266 for the internal standard (IS). The limit of quantification in plasma for all three analytes was 1ng/mL. The method was validated over a linear range from 1 to 500ng/mL for all three analytes with acceptable inter- and intra-assay precision and accuracy. The stability of the analytes was determined to be suitable for routine laboratory practices. The method was successfully applied to samples taken from research volunteers who ingested a 15mg tolvaptan tablet.
Collapse
|